Topic: Stoic Trial

Dr. Richard Bartlett discusses the efficacy of inhaled budesonide, citing the Oxford University STOIC trial which suggested a 90% reduction in COVID-19 hospitalizations. He explains the medical mechanism of how steroids down-regulate ACE receptors and stop cytokine storms in the lungs. Bartlett defends his protocol against media criticism, noting its long history of safe use in premature infants.

Dr. Bartlett cites the STOIC trial from Oxford University, which found that inhaled budesonide could prevent 90% of COVID-related hospitalizations. He compares this to the use of dexamethasone in ICUs, noting that early intervention with an inexpensive, generic steroid is a more effective strategy. The medicine is described as safe and widely available in pharmacies.

Dr. Richard Bartlett discusses the results of the Stoic trial from Oxford University, which suggested that inhaled budesonide could prevent 90% of COVID-19 hospitalizations. He explains the mechanism of Regeneron's monoclonal antibodies, describing them as a "search and destroy mission" for the virus. Bartlett advocates for early outpatient therapy over the strategies of lockdowns and social distancing derived from China.